Category: Uncategorized

Bionest

EU Proposes the First Pharmaceutical Legislation Reforms in Two Decades

EU Pharma legislation needs a makeover, but stakeholders disagree on the right approach. We look at the EC's long-anticipated proposals.

Bionest

Prospects for Improving Parkinson’s Disease Care through Wearable Health Tech

How might wearable health monitoring systems improve treatment for Parkinson's Disease and other neurological conditions?

Bionest

KRAS: Undruggable No More

The most frequently mutated oncogene in solid tumors, KRAS has been considered undruggable. Until now.

Bionest

New Treatment Options for Hemoglobin-Based Blood Disorders

Sickle cell disease is a group of inherited disorders that affects hemoglobin, the oxygen-carrying protein in red blood cells (RBCs), and causes these cells to distort in shape at low oxygen levels. This condition affects 1 in 500…

Bionest

New Treatments for Alzheimer’s Disease? Maybe.

The Alzheimer’s Association estimates that nearly six million Americans are living with the disease, a number that is expected to rise to 14 million by 2050. Marketed drugs such as memantine and donepezil modestly slow memory loss in some…

Bionest

Happy New Year! Here Are Three Key Areas to Watch in 2016

First of all, we at Bionest want to wish you a very happy, healthy, and prosperous new year.  And we look forward to speaking to many of you in person during JP Morgan week in San Francisco!   Another year ended. Another begun. In the time-honored tradition of year-end wrap-ups and new year’s predictions, we...